Monitoring Agency Report for the quarter ended June 30, 2026

Ref: Akums/Exchange/2026-27/40 August 10, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Symbol: AKUMS Scrip Code: 544222 Sub: Report of CRISIL Ratings Limited, Monitoring Agency Respected Sir/Ma’am, Pursuant to the Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed herewith the report of CRISIL Ratings Limited, Monitoring Agency dated August 10, 2026, in respect of utilization of proceeds of Initial Public Offer of Akums Drugs and Pharmaceuticals Limited for the quarter ended June 30, 2026. This is for your kind information and records. Thanking You Yours Faithfully For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer Encl.: As Above Monitoring Agency Report Akums Drugs and Pharmaceuticals Limited for the quarter ended June 30, 2026 CRL/MAR/GDS655/2026-27/1977 August 10, 2026 Akums Drugs and Pharmaceuticals Limited 304, Mohan Place LSC, Saraswati Vihar, Delhi-110034 Dear Sir, Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to the Initial Public Offer (“IPO”) of Akums Drugs and Pharmaceuticals Limited (“the Company”) Pursuant to Regulation 41(2) of SEBI (lssue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) and Monitoring Agency Agreement dated July 24, 2024, enclosed herewith the Monitoring Agency Report, issued by CRISIL Ratings Limited, Monitoring Agency, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of IPO for the quarter ended June 30, 2026. Request you to kindly take the same on records. Thanking you, For and on behalf of CRISIL Ratings Limited Shounak Chakravarty Director, Ratings (LCG) Report of the Monitoring Agency (MA) Name of the issuer: Akums Drugs and Pharmaceuticals Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: Crisil Ratings Limited (a) Deviation from the objects: Not applicable (b) Range of Deviation: Not applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name and designation of the Authorized Signatory: Shounak Chakravarty Designation of Authorized person/Signing Authority: Director, Ratings (LCG) 1) Issuer Details: Name of the issuer: Akums Drugs and Pharmaceuticals Limited Names of the promoter: a. Sandeep Jain b. Sanjeev Jain c. Akums Master Trust Industry/sector to which it belongs: Pharmaceuticals 2) Issue Details Issue Period: Tuesday, July 30, 2024 to Thursday, August 1, 2024 Type of issue (public/rights): Initial Public Offer (IPO) Type of specified securities: Equity Shares IPO Grading, if any: NA Issue size: Fresh issuance of Rs 6,800.00 million (Refer Note 1) Note : Particulars Amount as per the Prospectus (Rs. in million) Gross Proceeds 6,800.00* Less: Revised Offer Expenses (Refer Note 1) 378.21** Revised Net Proceeds (Refer Note 1) 6,421.80 All figures in the above table are rounded off to nearest two decimal places *Crisil Ratings shall be monitoring the gross proceeds. **As per the Prospectus dated August 01, 2024, the approximate issue related expense is Rs 426.30 million revised to Rs 378.21 million as per board resolution dated February 13, 2026. The issue expenses paid till the quarter ended June 30, 2026 amounts to Rs. 377.23 million with the remaining Rs 0.98 million lying unutilised in the Public Offer account as per the Management Undertaking & Certificate dated August 3, 2026, issued by M/s V. P. Gupta & Co., Chartered Accountants (Firm Registration Number: 000699N), Peer Reviewed Independent Chartered Accountant. 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information/ Comments Comments certifications considered of the of the Particulars Reply by Monitoring Agency Monitoring Board of for preparation of report Agency Directors Management undertaking, Peer- Nil Whether all utilization is as per the disclosures reviewed Independent utilization No in the Offer Document? Chartered Accountant during the Comments certificate^, Prospectus, quarter Bank Statements Whether shareholder approval has been obtained in case of material deviations from No No expenditures disclosed in the Offer Comment Comments Document? Whether the means of finance for the disclosed No No objects of the issue has changed? Comment Comments Is there any major deviation observed over the No No earlier monitoring agency reports? Comment Comments Whether all Government/statutory approvals Management No No related to the object(s) have been obtained? undertaking, Peer- Comment Comments reviewed Independent Whether all arrangements pertaining to Chartered Accountant No No technical assistance/collaboration are in NA certificate^ Comment Comments operation? Are there any favorable events improving the No No viability of these object(s)? Comment Comments Are there any unfavorable events affecting the No No viability of the object(s)? Comment Comments Is there any other relevant information that No No may materially affect the decision making of No Comment Comments the investors? NA represents Not Applicable ^Certificate dated August 3, 2026, issued by M/s V. P. Gupta & Co., Chartered Accountants (Firm Registration Number: 000699N), Peer Reviewed Independent Chartered Accountant. 4) Details of object(s) to be monitored: i. Cost of the object(s): Comments of the Board of Source of Original Directors information/ cost Revised Comment Particu certification (as per the Sr. Cost of the lars of Item considered Offer Reason Proposed No. (Rs in Monitoring firm Head by MA for Document) of Cost financing million) Agency arrang preparation (Rs in revision option ements of report million) made Repay [Showing first 8,000 characters — download PDF for full document]